Katie Jeans, MD
Pulmonary Disease · Murray, UTNPI 1093151862
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,366 and has fallen 94.4% since, to $76 in 2025.
Across 192 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$555
- Mylan Specialty L.p.$298
- GSK$289
- Boehringer Ingelheim$240
- United Therapeutics Corporation$189
- Pulmonx Corporation$175
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,479100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $555 |
| Mylan Specialty L.p. | 14 | $298 |
| GSK | 21 | $289 |
| Boehringer Ingelheim | 11 | $240 |
| United Therapeutics Corporation | 10 | $189 |
| Pulmonx Corporation | 9 | $175 |
| Amgen | 7 | $166 |
| Axsome Therapeutics, Inc. | 9 | $163 |
| Harmony Biosciences LLC | 8 | $134 |
| Sanofi | 7 | $120 |
| Abbott | 5 | $110 |
| Insmed, Inc. | 6 | $91 |
| ANI Pharmaceuticals, Inc. | 3 | $85 |
| Idorsia Pharmaceuticals US Inc | 4 | $80 |
| Jazz Pharmaceuticals Inc. | 4 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 4 | $66 |
| Bayer | 4 | $62 |
| Inspire Medical Systems, Inc. | 3 | $59 |
| Gilead | 3 | $57 |
| Baxter Healthcare | 3 | $56 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Grifols USA, LLC | 2 | $38 |
| Philips North America LLC | 2 | $33 |
| Merck | 2 | $31 |
| Electromed, Inc. | 2 | $27 |
| Resmed Corp | 2 | $27 |
| Astellas Pharma US Inc | 1 | $16 |
| AbbVie | 1 | $15 |
| Pfizer | 1 | $13 |
| Fisher & Paykel Healthcare Inc | 1 | $13 |
| Atricure, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$3,479 in reported general payments places this provider in the 70th percentile of 101 pulmonary disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 134 | $115,107 |
| Spiriva RespimatTiotropium Bromide | 63 | $60,643 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $55,017 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $47,028 |
| Dupixent PenDupilumab | 12 | $44,904 |
| Breo ElliptaFluticasone/Vilanterol | 58 | $33,498 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 164 | $27,868 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $25,231 |
| Advair HfaFluticasone Propion/Salmeterol | 49 | $19,812 |
| EliquisApixaban | 18 | $19,555 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $13,828 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 210 | $8,064 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $7,444 |
| Varenicline Tartrate | 15 | $4,558 |
| DuleraMometasone/Formoterol | 13 | $4,228 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $289 | $162,433203 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $240 | $107,671129 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $555 | $80,247138 claims |
| PfizerEliquis | $13 | $19,55518 claims |
| MerckDulera | $31 | $4,22813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 pulmonary disease providers in Utah.
Other pulmonary disease in Murray
- Timothy LeclairMurray$74K
- Sunny PanditaMurray$25K
- Meghan CirulisMurray$18K
- David GuidryMurray$11K
- David DienhartMurray$11K
- Lynette BrownMurray$10K
- Gregory GrandioMurray$6K
- Mark DodsonMurray$2K
- Samuel BrownMurray$1K
- Jeffrey GrahamMurray$408
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.